Shares of Sanofi-Aventis are getting a little investor injection on the back of the emergency release of the Lantus diabetic insulin studieslate last Friday. The stock had fallen about 10 percent late ...
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed! he year 2025 has pretty ...
It was Sanofi's first public event without ex-CEO Chris Viehbacher. But the French drugmaker's investor day didn't bring much in the way of surprise. As expected ...
Merck announced that two Phase 3 studies evaluating MK-1293, an investigational, follow-on biologic insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes, achieved ...
Would you please explain how to convert 70/30 insulin coverage to Lantus coverage? When our patients are admitted to the hospital, they are usually converted to Lantus with a sliding scale. Patient AB ...
NEW ORLEANS--Merck & Co. won’t be the first to roll out a biosimilar version of Sanofi’s multibillion-dollar basal insulin, Lantus. But it aims to step up the competition when it does--and new data ...
The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results